Assyro AI
FDA Orange Book · active-ingredient family

Metformin hydrochloride; rosiglitazone maleate

Metformin hydrochloride; rosiglitazone maleate: 1 brand, 1 generic; first approved Oct 10, 2002; generic available.

Generic availableHas discontinued products
Generic status & protection

Generic available — 1 ANDA application approved.

Brands (NDA)
1
Generics (ANDA)
1
Listed patents
0
Presentations
10
Originator applications

Brand (NDA) products

NDA 02141020035 strengths
Approved strengths under this FDA application.
StrengthDosage formRouteStatusTE
500MG;EQ 1MG BASE **Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons**TABLETORALDiscontinued
500MG;EQ 2MG BASE **Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons**TABLETORALDiscontinued
500MG;EQ 4MG BASE **Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons**TABLETORALDiscontinued
1GM;EQ 2MG BASE **Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons**TABLETORALDiscontinued
1GM;EQ 4MG BASE **Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons**TABLETORALDiscontinued
Abbreviated applications

Generic (ANDA) products (1)

Approved strengths under this FDA application.
StrengthDosage formRouteStatusTE
500MG;EQ 2MG BASETABLETORALDiscontinued
500MG;EQ 4MG BASETABLETORALDiscontinued
1GM;EQ 2MG BASETABLETORALDiscontinued
1GM;EQ 4MG BASETABLETORALDiscontinued
500MG;EQ 1MG BASETABLETORALDiscontinued
Orange Book patent file

Listed patents

Listed patents

No patents are listed against this product in the Orange Book. Listed patents reflect those the NDA holder submits under 21 U.S.C. 355 and are not exhaustive.

FDA approval span

Approval history

First approval
Oct 10, 2002
24 yr 1 mo ago
Most recent approval
May 19, 2017
9 yr 3 mo ago

Approvals span 2002–2017 across 2 FDA applications.

Brand (NDA) 150%
Generic (ANDA) 150%

Metformin hydrochloride; rosiglitazone maleate — frequently asked questions

Generics, reference-listed drug, patents, and exclusivity for this active ingredient, from the FDA Orange Book.

Built directly from the FDA Orange Book data file (products, patents, and exclusivity). TE codes, RLD/RS flags, patent expirations, and exclusivity dates match the official FDA record. Listed patents reflect those the NDA holder submits under 21 U.S.C. 355 and are not exhaustive.

Related FDA reference tools

Agent CTA Background

Your Next Submission Could Take 6+ Fewer Weeks and Cost $250K Less.